Selank
NOT FDA APPROVEDCognitive / anxiolytic peptide
Also known as: TP-7
Not FDA approved. Completed Phase III trials in Russia for generalized anxiety disorder; sold elsewhere as a research chemical.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 2 registered studies on ClinicalTrials.gov
- 1 cited source. Includes primary / regulatory sources
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven mostly in Russian trials, where it has anxiolytic (anti-anxiety) and neuroprotective effects and reached Phase III for GAD. Independent Western replication is limited, so the effect size is not firmly established by FDA-grade standards.
What it is
A synthetic analog of the immunomodulatory peptide tuftsin, proposed to influence GABA and serotonin systems.
What the research says
Russian clinical studies report anxiolytic and neuroprotective effects; reached Phase III for GAD there.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Selank in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Natural and hybrid ("chimeric") stable regulatory glyproline peptides.
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.
Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.
[Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation].
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Selank is the intervention being tested.
FDA recalls & enforcement
Selank has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Limited independent safety data outside its country of registration.
- Gray-market purity varies.
Doses reported in studies & protocols
Intranasal protocols vary. No FDA-established dose. This is not a recommendation.
Purity reality
A COA is the only way to confirm content.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.